))
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
Manage episode 444073225 series 3381434
Контент предоставлен ReachMD. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией ReachMD или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
CME credits: 1.00
Valid until: 04-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/bringing-treatment-into-focus-biomarker-driven-first-line-therapy-for-metastatic-gastricgej-cancers/26719/
This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (GEJ) cancers. Participants will explore the latest clinical trial data and emerging biomarkers that guide treatment decisions. Our experts emphasize selecting optimal therapies tailored to patient-specific factors and offer strategies for managing treatment-related adverse effects. Tune in to enhance treatment efficacy and patient outcomes for your patients with metastatic gastric/GEJ cancers.=
…
continue reading
Valid until: 04-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/bringing-treatment-into-focus-biomarker-driven-first-line-therapy-for-metastatic-gastricgej-cancers/26719/
This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (GEJ) cancers. Participants will explore the latest clinical trial data and emerging biomarkers that guide treatment decisions. Our experts emphasize selecting optimal therapies tailored to patient-specific factors and offer strategies for managing treatment-related adverse effects. Tune in to enhance treatment efficacy and patient outcomes for your patients with metastatic gastric/GEJ cancers.=
453 эпизодов
Поделиться
